Click Guardian v2 Tracking Pixel
Appointment

Dr Nathalie Jacque

Clinical Hematology Consultant

Locationsموقعنا
CMC Hospital – DHCC 2
Languagesاللغات
English French

Bio

السيرة

Dr Nathalie Jacque is a consultant hematologist in CMC Dubai. She received her French Board of Hematology in 2011 after 6 years of residency in Paris.

After her graduation, she began a research program at Cochin Institute working on treatment of acute leukemia. She obtained her PhD in Hematology and Oncology from Paris Sorbonne University in 2015.

At the same time, she was a consultant hematologist in Pitié Salpêtrière Hospital in Paris. She was first in charge of an intensive care unit (chemotherapy for acute leukemia, autologous and allogeneic stem cell transplantation) and then of the daily care hospital (treatments of lymphomas, myelomas, myelodysplastic syndromes, acute leukemias; post allogeneic SCT consultations; Immunoglobuline and blood transfusions; iron therapy).

She is a member of the Lymphoma study association (LYSA), Francophone Myeloma Intergroup (IFM), French society of bone marrow transplant and cellular therapy (SFGM-TC).

Treatments
العلاجات
  • Diagnosis and treatment of all hematological disorders either benign or malignant: anemia, cytopenias, immunodeficiency, myeloid and lymphoid cancers.
  • Chemotherapy and oral therapy, iron and immunoglobuline perfusions and blood transfusion.
  • Bone marrow biopsy and aspirations, lumbar puncture
Education
التعليم

Ecole Doctorale Hématologie Oncogenèse Biothérapies Paris Sorbonne University, PHD 2015

Doctor of Medecine (MD), Paris VI University, Hematology Specialty. 2011

Master of Science, Paris V, « Cellular biology, physiology, pathology, 2010

Medical Residency, Paris, 2005-2011

Publications
  • Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. Forgeard N, Baron M, Caron J, Boccon-Gibod C, Krzisch D, Guedes N, Morel V, Jacque N, Ouzegdouh M, Choquet S, Bravetti C, Nguyen-Khac F, Chapiro E, Leblond V, Roos-Weil D. Haematologica. 2022
  • CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network. Alcantara M, Houillier C, Blonski M, Rubio MT, Willems L, Waultier Rascalou A, Le Garff-Tavernier M, Maloum K, Bravetti CM, Souchet L, Roos-Weil D, Morel V, Uzunov M, Metz C, Dhib-Charfi M, Nguyen S, Shor N, Psimaras D, Weiss N, Jacque N, Solorzano S, Gauthier N, Le Cann M, Norol F, Soussain C, Choquet S. Blood. 2021
  • How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Garnache-Ottou F, Vidal C, Biichlé S, …, Jacques N …, Deconinck E. Blood Adv. 2019
  • Chronic lymphocytic leukemia Jacque N, Leblond V. Presse Med. 2019
  • RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J. Leukemia. 2018
  • Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Sci Adv. 2015
  • Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Thiago TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Blood. 2015
  • Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia. Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decroocq J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J. Cell Rep. 2015
  • Targeting glutamine uptake in AML. Jacque N, Bouscary D. Oncoscience. 2014
  • Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. Jacque N, Nguyen S, Golmard JL, Uzunov M, Garnier A, Leblond V, Vernant JP, Bories D, Dhédin N. Bone Marrow Transplant. 2015
  • The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Leukemia. 2012
  • The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Br J Haematol. 2012

Related services

الخدمات ذات الصلة

Start chat
1
Chat with us
Hello
I’d like to book an appointment